Pharmacogenetic Characterization of Cytochrome P450 Genes involved in Psychotropic Medication Metabolism in a Cohort of Patients with Prader-Willi Syndrome
Moreno-Armengol, A.; Pareja, R.; Hernandez-Lazaro, A.; Capel, L.; Corripio, R.; Caixas, A.; Baena, N.
Show abstract
Prader-Willi syndrome (PWS) is a rare multisystemic disorder characterized by obesity, endocrine dysfunctions, and psychiatric comorbidities, which imply frequent use of psychotropic medications. They account for atypical responses to standard dosages of psychiatric drugs. Pharmacogenetics could be part of the reason for this situation, potentially offering a valuable tool for individualized treatment. This study analyzed allelic and phenotypic frequency distributions of five of the main cytochrome P450 enzymes (CYP2D6, CYP2B6, CYP2C19, CYP2C9, CYP3A4) involved in psychiatric drug metabolism in 47 patients with genetically confirmed diagnosis of PWS and compared them to reference frequencies in the general European population. Allelic frequency comparisons between the European reference population and the overall PWS cohort revealed a significant global difference for CYP2B6, with CYP2C19 and CYP2D6 showing trends toward significance. Although no global allelic differences remained significant after false discovery rate correction, post-hoc analyses consistently identified an enrichment of reduced- or non-functional alleles CYP2B619 and CYP2D610 in patients with PWS. Predicted metabolizer phenotype analyses showed a significant shift toward intermediate metabolizers of CYP3A4 in the PWS cohort, with corresponding depletion of normal metabolizers. Subgroup analyses indicated that allelic differences were more pronounced in maternal uniparental disomy and non-deletion subtypes, particularly for CYP2B6, although no significant differences were observed between PWS genetic subtypes. Overall, results imply potential differences in metabolizing activity in PWS patients, and subsequent implications in drug efficacy and tolerability. These results support the idea that pharmacogenetic testing may improve therapeutic decision-making in PWS for psychiatric treatment. Larger studies are needed to confirm these preliminary results.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The influence of CYP2D6 and CYP2C19 genetic variation on diabetes mellitus risk in people taking antidepressants and antipsychotics 93%
- A novel co-segregating DCTN1 splice site variant in a family with Bipolar Disorder may hold the key to understanding the etiology 92%
- Predictive value of SLCO1B1 c.521T>C polymorphism on observed changes in the treatment of 1136 statin-users 91%
Similar papers in this journal
- SLCO1B1 functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study 90%
- Pharmacogenetics at scale: An analysis of the UK Biobank 90%
- Biobank scale pharmacogenomics informs the genetic underpinnings of simvastatin use 89%
Similar papers in this journal
- Mediation and Longitudinal Analysis to interpret the association between clozapine pharmacokinetics, pharmacogenomics, and absolute neutrophil count 91%
- Adverse effects of antipsychotic drugs on metabolism depend on drug dosing and feeding times 88%
- Clozapine prescribing in Germany: temporal trends and regional variations, 2012 to 2022 88%
Similar papers in this journal
- Clozapine metabolism is associated with Absolute Neutrophil Count in individuals with treatment-resistant schizophrenia 91%
- Loss of multiple enzyme activities due to the human genetic variation P284T in NADPH cytochrome P450 oxidoreductase 91%
- Near, far, wherever you are: Phenotype-related variation in pharmacogenomic effect sizes across the psychiatric drug literature. 89%
Similar papers in this journal
- Population Pharmacokinetic Analysis of Dexmedetomidine in Children using Real-World-Data Obtained from Electronic Health Records and Remnant Clinic Samples 89%
- A comprehensive assessment of statin discontinuation among patients who concurrently initiate statins and CYP3A4-inhibitor drugs; a multistate transition model 88%
- External validation of the predictive performance of population pharmacokinetic models for phenobarbital in pediatric patients 88%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.